Skip to main content

Table 4 Haemagglutination inhibition antibody immune responses against TIV strains (According To Protocol cohort for immunogenicity)

From: A randomized, controlled non-inferiority trial comparing A(H1N1)pmd09 vaccine antigen, with and without AS03 adjuvant system, co-administered or sequentially administered with an inactivated trivalent seasonal influenza vaccine

Strain

Time point

Group

Na

Seroconversion rate

Seroprotection rate

Geometric mean fold rise >2.5

Geometric mean titre

    

Value or % [95% CIa]

A/Brisbane/59/2007

Day 21

A

92

77.2% [67.2-85.3%]

93.5% [86.3-97.6%]

8.4 [6.5-10.8]

145.1 [115.9-181.6]

 

B

86

86.0% [76.9-92.6%]

97.7% [91.9-99.7%]

12.9 [10.0-16.6]

215.7 [168.2-276.5]

 

C

92

82.6% [73.3-89.7%]

96.7% [90.8-99.3%]

12.0 [9.4-15.4]

226.3 [181.4-282.2]

 

D

88

79.5% [69.6-87.4%]

92.1% [84.5-96.8%]

9.6 [7.7-12.1]

158.7 [127.9-197.1]

Day 42

E

91

18.7% [11.3-28.2%]

51.6% [40.9-62.3%]

2.3 [1.9-2.6]

32.9 [27.3-39.7]

 

F

91

30.8% [21.5-41.3]

68.1% [57.5-77.5%]

3.2 [2.7-3.8]

53.2 [43.5-65.1]

Day 63

A

92

68.5% [58.0-77.8%]

91.3% [83.6-96.2%]

6.9 [5.4-8.9]

120.2 [96.5-149.7]

 

B

86

88.4% [79.7-94.3%]

100% [95.8-100%]

11.2 [9.1-13.7]

186.5 [150.4-231.4]

 

C

92

75.0% [64.9-83.4%]

92.4% [84.9-96.9%]

8.4 [6.6-10.6]

157.0 [126.0-195.8]

 

D

88

72.7% [62.2-81.7%]

88.8%[80.3-94.5%]

7.6 [6.0-9.5]

124.3 [99.0-156.1]

 

E

91

78.0% [68.1-86.0%]

89.0% [80.7-94.6%]

9.4 [7.6-11.7]

137.4 [109.0-173.1]

 

F

91

83.5% [74.3-90.5%]

95.6% [89.1-98.8%]

10.1 [8.1-12.6]

166.9 [132.5-210.3]

Day 182

A

92

48.9% [38.3-59.6%]

68.5% [58.0-77.8%]

4.0 [3.1-5.3]

68.5 [53.6-87.4]

 

B

89

64.0% [53.2-73.9%]

83.1% [73.7-90.2%]

5.2 [4.2-6.6]

89.2 [71.0-112.0]

 

C

85

52.9% [41.8-63.9%]

77.6% [67.3-86.0%]

4.7 [3.7-6.0]

87.4 [68.5-111.5]

 

D

89

43.2% [32.7-54.2%]

68.5% [57.8-78.0%]

3.7 [2.9-4.8]

64.6 [51.4-81.1]

 

E

89

51.7% [40.8-62.4%]

75.3% [65.0-83.8%]

4.4 [3.5-5.4]

64.6 [51.4-81.1]

  

F

91

59.3% [48.5-69.5%]

78.0% [68.1-86.0%]

5.0 [4.0-6.3]

83.7 [66.0-106.2]

A/Uruguay/716/2007

Day 21

A

92

78.3% [68.4-86.2%]

84.8% [75.8-91.4%]

17.4 [13.0-23.3]

175.7 [129.6-238.2]

 

B

86

84.9% [75.5-91.7%]

89.5% [81.1-95.1%]

15.5 [11.8-20.4]

183.5 [135.2-248.9]

 

C

92

78.3% [68.4-86.2%]

83.7% [74.5-90.6%]

20.6 [14.8-28.6]

181.7 [128.1-257.9]

 

D

88

86.4% [77.4-92.8%]

88.8% [80.3-94.5%]

19.3 [14.2-26.4]

191.4 [138.4-264.7]

Day 42

E

91

3.3% [0.7-9.3%]

19.8% [12.2-29.4%]

1.2 [1.1-1.4]

12.5 [10.0-15.6]

 

F

91

6.6% [2.5-13.8%]

30.8% [21.5-41.3%]

1.7 [1.5-1.9]

19.1 [15.6-23.4]

Day 63

A

92

77.2% [67.2-85.3%]

84.8% [75.8-91.4%]

13.3 [10.0-17.6]

134.4 [100.4-179.9]

 

B

86

80.2% [70.2-88.0%]

87.2% [78.3-93.4%]

11.7 [9.1-15.0]

138.4 [104.8-182.7]

 

C

92

75.0% [64.9-83.4%]

79.3% [69.6-87.1%]

15.0 [11.2-19.9]

132.0 [94.9-183.7]

 

D

88

78.4% [68.4-86.5%]

84.3% [75.0-91.1%]

14.6 [10.9-19.6]

145.6 [107.7-196.8]

 

E

91

82.4% [73.0-89.6%]

89.0% [80.7-94.6%]

20.8 [15.5-28.0

216.1 [160.0-292.0]

 

F

91

85.7% [76.8-92.2%]

91.2% [83.4-96.1%]

19.3 [14.6-25.5]

221.9 [167.2-294.6]

Day 182

A

92

63.0% [52.3-72.9%]

71.7% [61.4-80.6%]

9.0 [6.7-11.9]

89.5 [65.8-121.8]

 

B

89

62.9% [52.0-72.9%]

71.9% [61.4-80.9%]

7.2 [5.6-9.3]

87.7 [64.0-120.3]

 

C

85

63.5% [52.4-73.7%]

70.6% [59.7-80.0%]

9.7 [7.2-13.1]

87.1 [61.4-123.5]

 

D

89

63.6% [52.7-73.6%

71.9% [61.4-80.9%]

8.5 [6.2-11.7]

87.8 [63.4-121.4]

 

E

89

67.4% [56.7-77.0%]

76.45 [66.2-84.85]

9.9 [7.3-13.5]

110.0 [79.3-152.6]

  

F

91

67.0% [56.4-76.5%]

76.9% [66.9-85.1%]

10.6 [7.9-14.2]

127.2 [92.3-175.5]

B/Brisbane/60/2008

Day 21

A

92

82.6% [73.3-89.7%]

98.9% [94.1-100%]

12.6 [9.8-16.2]

662.1 [545.4-803.8]

 

B

86

88.4% [79.7-94.3%]

98.8% [93.7-100%]

13.9 [11.1-17.5]

658.3 [540.2-802.0]

 

C

92

80.4% [70.9-88.0%]

97.8% [92.4-99.7%]

10.5 [8.3-13.5]

478.8 [389.5-588.6]

 

D

88

88.6% [80.1-94.4%]

100% [95.9-100%]

14.3 [11.0-18.7]

576.1 [479.8-691.8]

Day 42

E

91

6.6% [2.5-13.8%]

82.4% [73.0-89.65]

1.3 [1.1-1.5]

74.7 [61.4-90.9]

 

F

91

26.4% [17.7-36.7%]

97.8% [92.3-99.7%]

2.4 [2.0-2.8]

139.5 [120.0-162.2]

Day 63

A

92

79.3% [69.6-87.1%]

98.9% [94.1-100%]

9.6 [7.5-12.4]

506.7 [422.3-608.0]

 

B

86

84.9% [75.5-91.7%]

100% [95.8-100%]

10.0 [8.1-12.2]

471.2 [396.3-560.2]

 

C

92

72.8% [62.6-81.6%]

98.9% [94.1-100%]

7.9 [6.3-9.9]

359.6 [299.4-431.9]

 

D

88

83.0% [73.4-90.1%]

100% [95.9-100%]

10.8 [8.4-13.7]

433.5 [369.5-508.7]

 

E

91

85.7% [76.8-92.2%]

100% [96.0-100%]

11.4 [9.1-14.2]

644.9 [534.5-778.2]

 

F

91

83.5% [74.3-90.5%]

100% [96.0-100%]

11.9 [9.4-15.0]

688.1 [593.0-798.6]

Day 182

A

92

73.9% [63.7- 82.5%]

97.8% [92.4-99.7%]

6.7 [5.2-8.6]

339.9 [276.7-417.5]

 

B

89

60.7% [49.7-70.9%]

98.9% [93.9-100%]

5.7 [4.5-7.1]

273.8 [228.7-327.9]

 

C

85

56.5% [45.3-67.2%]

92.9% [85.3-97.4%]

5.5 [4.3-6.9]

245.4 [197.8-304.3]

 

D

89

72.7% [62.2-81.7%]

100% [95.9-100%]

6.8 [5.3-8.6]

292.6 [247.0-346.7]

 

E

89

75.3% [65.0-83.8%]

98.9% [93.9-100%]

6.9 [5.4-8.7]

369.6 [300.0-455.3]

  

F

91

68.1% [57.5-77.5%]

100% [96.0-100%]

6.4 [5.0-8.1]

378.4 [323.4-442.8]

  1. a N = Number of subjects with available results.
  2. b LL = Lower limit.
  3. c CI = Confidence Interval.